Loading
A phase 3 trial of an investigational treatment in non-small-cell lung cancer, run by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., active and no longer recruiting.
Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC is a phase 3 interventional study registered as NCT06569420 by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., with 275 participants enrolled, started 2021-12-31 and due to reach its primary completion in 2025-07-31.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Shanghai Fosun Pharmaceutical Industrial Development and the tag pipeline.
Shares Shanghai Fosun Pharmaceutical Industrial Development, Non-small-cell lung cancer and the tag pipeline.
Shares Shanghai Fosun Pharmaceutical Industrial Development and the tag pipeline.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/